VNRX, US9286612067

Nasdaq cuts target for VolitionRx stock to USD 13.89

Published on 10/14/2026 at 06:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The average target fell 17.44 percent to USD 13.89 on October 2, 2026. VolitionRx stock gets Q2 revenue context at USD 398,000.

Analyst target and results date

Nasdaq reported a 17.44 percent reduction in the average VolitionRx target to USD 13.89 on October 2, 2026.
Second-quarter revenue was USD 398,000 against a USD 492,323 estimate.
VolitionRx is scheduled to report its next results on November 12, 2026.

VNRX, US9286612067, Illustration mit AI erstellt.

VolitionRx (ISIN US9286612067) faces a lower analyst valuation after Nasdaq reported on October 2, 2026, that the average one-year target fell 17.44 percent from USD 16.83 to USD 13.89. The revision puts financing progress and commercial evidence at the center of the investment case.

What changed in analyst expectations?

According to Nasdaq on October 2, 2026, the average target was reduced to USD 13.89 from USD 16.83. The same report said the target represented an aggregate of analyst estimates, while the latest reported closing price used in that comparison was USD 0.23 on October 1, 2026.

The latest reported operating comparison was also unfavorable. Nasdaq said VolitionRx generated USD 398,000 of revenue in the second quarter of 2026 against a USD 492,323 estimate, a revenue shortfall of 19.16 percent.

Three dated company developments

On September 14, 2026, VolitionRx announced the cash prepayment of a USD 7.5 million senior secured convertible note. The company said the repayment removed that note's remaining obligations and reduced a potential source of dilution.

On September 17, 2026, MarketScreener reported that VolitionRx had joined the French government-funded DETECSEPS consortium, backed by EUR 6.3 million. Volition is supplying its Nu.Q NETs assay as the sole biomarker for a real-world evaluation of early sepsis detection.

On October 2, 2026, the target revision became the latest dated development in this chronology. Together, the events show a company reducing one financing overhang while seeking clinical and commercial validation for its diagnostic platform.

When are results due?

Investing.com lists November 12, 2026 as VolitionRx's next results date. That report will give investors a fresh test of revenue conversion after the second-quarter revenue comparison and will show whether the September sepsis program has begun to create measurable commercial traction.

Market value and listing

VolitionRx had a market capitalization of USD 1.5 million as of October 13, 2026. Stock Analysis identifies the company as VolitionRx Limited, ticker VNRX, listed on NYSE American, with a healthcare and medical devices profile.

Market context: Market report S&P 500.